



# MEDICAMEN Organics Limited

Regd. & Corporate Office: 10, Community Centre No.2, Ashok Vihar Phase-II, Delhi-110052 (India)

Tel: 011-27430249, 27138171

E-mail: info@mediorganics.in | CIN No: L74899DL1995PLC066416 | GSTIN:07AABCM4302P1ZF

November 14, 2024

To,  
**National Stock Exchange of India Limited**  
**Listing & Compliance Department**  
Exchange Plaza, 5<sup>th</sup> Floor, Plot No. C/1,  
G Block, Bandra-Kurla Complex, Bandra  
Mumbai - 400051, India

Company Symbol : **MEDIORG**  
Company ISIN : **INE0PE401018**

**Subject: Outcome of Board meeting held on Thursday, November 14, 2024, under Regulations 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

Dear Sir / Madam,

We wish to inform you that, in terms of Regulations 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Board of Directors of the Company at its duly convened meeting held today i.e. Thursday, November 14, 2024 inter-alia:

1. considered, approved and took on record the Un-Audited Financial Results, duly reviewed by the Audit Committee, along with Limited Review Report submitted by the Statutory Auditors of the Company for the half year ended on September 30, 2024. A copy of the said unaudited financial results along with the Limited Review Report by Statutory Auditor thereon is attached as **Annexure-A**; and
2. considered, reviewed and approved the Statement of Deviation/ Variation in terms of 32(8) of SEBI (LODR), Regulations, 2015 for the half year ended September 30, 2024 for utilization of funds raised through Company's maiden public issue ("IPO"). A copy of the same is enclosed herewith as **Annexure-B**.

The meeting of Board of Directors commenced at 03:30 P.M. and concluded at 05:25 P.M.

The above information is also available on the website of company at [www.medicamenorganics.com](http://www.medicamenorganics.com).

You are requested to kindly take the same on your record.

Thanking You.  
For **Medicamen Organics Limited**

**Bal Kishan Gupta**  
**Managing Director**  
**DIN: 00032772**

Place: **New Delhi**

Encl.: as stated above

## Works:

**Unit-1** : Plot No. 60, Sector 6-A, I.I.E. SIDCUL, Haridwar- 249403 (U.K.) | **GSTIN**: 05AABCM4302P1ZJ

**Unit-2** : Plot No. 61, Sector 6-A, I.I.E. SIDCUL, Haridwar- 249403 (U.K.) | **GSTIN**: 05AABCM4302P3ZH

**N C RAJ & ASSOCIATES**

Chartered Accountants  
10, Community Centre No.2,  
Ashok Vihar Phase-II,  
Delhi – 110 052  
Phone: +919810831648  
+919810262603  
Website: www.ncraj.com  
Email: info@ncraj.com  
Peer Review No.: 014034

**Auditor's Limited Review Report on unaudited Standalone Financial results of Medicamen organics Limited, for the Half year ended September 30, 2024 pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.**

To,  
The Board of Directors of,  
Medicamen Organics Limited

We have reviewed the accompanying statement of unaudited Standalone financial results of **Medicamen organics Limited** for the half year ended September 30, 2024 being submitted by the company pursuant to the requirements of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015(as amended), including relevant circular issued by the SEBI from time from time.

The statement, which is the responsibility Of the Company's Management and has been approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Accounting Standard 25, 'Interim Financial Reporting' ('AS 25'), prescribed under section 133 of the Companies Act, 2013 (the Act'), SEBI Circular CIR/CFD/FAC/62/2016 dated 5<sup>th</sup> July, 2016, (herein after referred to as the SEBI Circular'), and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

We conducted our review of the statement in accordance with the Standard on Review Engagement (SRE) 2410 "Review of Interim Financial Information performed by the independent Auditor of the Entity", issued by the institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primary to inquire of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited Standalone financial results prepared in accordance with the recognition and measurement principles laid down in AS 25, prescribed under section 133 Of the Act the SEBI Circular, and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) including the manner in which it is to be disclosed, or that it contains any material misstatement.





**EMPHASIS OF MATTER**

- The company has not made Provision for the demand raised by various authorities (Such as Income Tax, GST etc.) as referred in **Note No 14** of unaudited financial results, as the matters are pending before various appellate forums. We are unable to comment upon possible impact of non-provision in the standalone financial statement for the half year ended 30<sup>th</sup> September 2024.
- In reference to **Note no. 14B** of the statement which explains the details of pending litigation (total 4 civil recovery suit) and all matters are pending before Rohini (Court Delhi).
- In reference to **Note no. 15** of the statement which explains statement of deviation/ variation in utilisation of funds raised thru IPO and auditor comments on such statement that there is no deviation in utilisation of funds.
- In reference to **Note No.16**, The Company has written off an amount of Rs. 36.24 Lakhs being outstanding balance of supplier due to some material rejections which is subject to confirmation from supplier. further an amount of Rs.16.04 Lakhs from other supplier was written off in the financial year 2023-24 which has now been written back in the current period due to disagreement with the party on material rejection.
- In reference to **Note No.17**, balances of some debtors and creditors are subject to their confirmations.
- In reference to **Note no. 18** of the statement which explains as per the assessment of the management, the recoverable amount of assets is higher than it carrying value and hence no impairment of assets needs to be recorded in the financial statements.

Our conclusion is not modified in respect of this matter.

For N C RAJ & ASSOCIATES  
Chartered Accountants  
(FRN: 002249N)



**SANJAY GARG**  
Partner  
Mem. No. 088636  
Date: November 14<sup>th</sup> 2024  
Place: New Delhi  
UDIN: 24088636BKARPG4659



## MEDICAMEN ORGANICS LIMITED

Registered Address: 10, Community Centre No 2, Ashok Vihar Phase II, New Delhi – 110052, India

CIN: L74899DL1995PLC066416

### STATEMENT OF UNAUDITED FINANCIAL RESULTS AS AT SEPTEMBER 30<sup>TH</sup>, 2024

(Rs. In Lakhs)

	PARTICULARS	Figures as at the end of	
		As At 30.09.2024	As At 31.03.2024
		Unaudited	Audited
<b>I.</b>	<b><u>EQUITY AND LIABILITIES</u></b>		
<b>1</b>	<b>Shareholders' funds</b>		
	(a) Share Capital	1170.00	860.00
	(b) Reserves and Surplus	1561.00	665.94
		<b>2731.00</b>	<b>1525.94</b>
<b>2</b>	<b>Share Application Money Pending Allotment</b>	-	-
<b>3</b>	<b>Non- current liabilities</b>		
	(a) Long-term borrowings	22.82	16.14
	(b) Deferred Tax liabilities	124.89	118.54
	(c) Long-term Provisions	24.77	21.47
		<b>172.48</b>	<b>156.15</b>
<b>4</b>	<b>Current Liabilities</b>		
	(a) Short term borrowings	1264.82	1249.51
	(b) Trade payables		
	- Outstanding dues of Micro and Small Enterprises	100.15	117.29
	- Outstanding dues to others	482.94	590.67
	(c) Other current liabilities	89.13	105.93
	(d) Short term provisions	58.44	66.01
		<b>1995.48</b>	<b>2129.42</b>
	<b>TOTAL</b>	<b>4898.95</b>	<b>3811.51</b>
<b>II</b>	<b><u>ASSETS</u></b>		
<b>1.</b>	<b>Non-current assets</b>		
	(a) Property, Plant & Equipment		
	(i) Property, Plant & Equipment	1038.48	1033.92
	(ii) Intangible assets	0.90	1.01
	(iii) Capital work-in-progress	14.63	14.63
	(b) Long-term Loans & Advances	-	-
	(c) Other Non-Current Assets	391.44	30.72
		<b>1445.44</b>	<b>1080.28</b>
<b>2.</b>	<b>Current assets</b>		
	(a) Inventories	659.81	614.26
	(b) Trade receivables	2016.52	1670.01
	(c) Cash and cash equivalents	201.76	55.30
	(d) Short-term loans and advances	575.41	391.66
	(e) Other current assets	-	-
		<b>3453.51</b>	<b>2731.23</b>
	<b>TOTAL</b>	<b>4898.95</b>	<b>3811.51</b>

For & on behalf of Medicamen Organics Limited

For MEDICAMEN ORGANICS LIMITED

*Bal Kishan Gupta*

Director

Bal Kishan Gupta

(Chairman cum Managing Director)

DIN:00032772

Place: New Delhi

Date: November 14th, 2024



# MEDICAMEN ORGANICS LIMITED

Registered Address: 10, Community Centre No 2, Ashok Vihar Phase II New Delhi – 110052, India

CIN: L74899DL1995PLC066416

STATEMENT OF UNAUDITED PROFIT AND LOSS FOR THE HALF YEAR ENDED SEPTEMBER 30<sup>TH</sup>, 2024

(Rs. In Lakhs)

	PARTICULARS	For the Half Year Ended			Figures as at the end of 31.03.2024
		From 01-04-2024 to 30-09-2024	From 01-10-2023 to 31-03-2024	From 01-04-2023 to 30-09-2023	
		Unaudited	Audited	Audited	Audited
I	Revenue from operations	1661.04	1395.17	1132.00	2527.17
II	Other Income	24.61	1.20	0.59	1.79
III	<b>Total Revenue (I + II)</b>	<b>1685.66</b>	<b>1396.37</b>	<b>1132.59</b>	<b>2528.96</b>
IV	<b>Expenses</b>				
	Cost of Materials Consumed	975.67	916.52	523.41	1439.94
	Direct Expenses	154.78	157.79	129.12	286.91
	Changes in inventories of finished goods, work in progress and Stock-in- trade	14.40	-151.65	4.66	-146.99
	Employee benefits expense	175.82	165.20	170.19	335.39
	Finance Costs	22.17	36.17	28.57	64.74
	Depreciation and amortization expense	36.41	36.09	35.85	71.94
	Other expense	87.55	73.96	64.18	138.15
	<b>Total Expense</b>	<b>1466.81</b>	<b>1234.10</b>	<b>955.99</b>	<b>2190.08</b>
V	<b>Profit before exceptional and extraordinary items and tax (III-IV)</b>	<b>218.84</b>	<b>162.27</b>	<b>176.61</b>	<b>338.88</b>
VI	Exceptional Items	-	-	-	-
VII.	<b>Profit before extraordinary items and tax (V-VI)</b>	<b>218.84</b>	<b>162.27</b>	<b>176.61</b>	<b>338.88</b>
VIII	Prior Period Item/Extraordinary items(Loss)	-	-	-104.81	-104.81
IX	<b>Profit before tax (VII-VIII)</b>	<b>218.84</b>	<b>162.27</b>	<b>281.41</b>	<b>443.69</b>
X	<b>Tax expense:</b>				
	(1) Current tax	61.43	50.55	45.65	96.20
	(2) Deferred tax	6.35	-14.45	99.51	85.06
XI	<b>Profit/(Loss) for the period from continuing operations (IX - X)</b>	<b>151.07</b>	<b>126.18</b>	<b>136.25</b>	<b>262.43</b>
XII	<b>Profit/(Loss) for the period</b>	<b>151.07</b>	<b>126.18</b>	<b>136.25</b>	<b>262.43</b>
XIII	<b>Earnings per equity share:</b>				
	(1) Basic	1.48	1.52	1.99	3.47
	(2) Diluted	1.48	1.52	1.99	3.47
	(Face Value of Rs. 10/- each)				

For & on behalf of Medicamen Organics Limited

For MEDICAMEN ORGANICS LTD

*Bal Kishan Gupta*

Director

Place: New Delhi

Date: November 14th, 2024

Bal Kishan Gupta  
(Chairman cum Managing Director)  
DIN:00032772



## MEDICAMEN ORGANICS LIMITED

Registered Address: 10, Community Centre No 2, Ashok Vihar Phase II New Delhi – 110052, India  
CIN: L74899DL1995PLC066416

### Notes to Unaudited Statement of Profit and Loss

- 1 The standalone unaudited financial results are prepared in accordance with the Accounting Standards Prescribed under Section 133 of the Companies Act, 2013 read with Rule 7 of the Companies (Accounts) Rules, 2014 (as amended) and other recognised accounting practices and policies, as applicable.
- 2 The company has signed a Memorandum of understanding (MOU) (dated 15th July 2024) and share sale agreement (dated 08 October 2024) with the Depot Pharmacy Yego Ltd. (Rwanda, East Africa based company) having corporate office at Plot No B1 Kigali City Market, Nyarugenge Kigali-20093, Rwanda East Africa. The company is planning to invest 51% stake in Depot Pharmacy Yego Ltd. The Company is in process to make payment and due diligence of the said company. The company has initiated the process of establishing subsidiary overseas as part of its growth strategy. However, since committed equity subscription has not yet occurred, consolidation is not applicable for the half-year ended September 30, 2024.
- 3 The Statutory Auditors of the Company have carried out a "Limited Review" of the above results as per Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015.
- 4 There were no investor complaints known to the Company outstanding at the beginning and at the end of the half year ended on September 30, 2024.
- 5 The results of the Company are also available for investors at [www.medicamenorganics.com](http://www.medicamenorganics.com), and [www.nseindia.com](http://www.nseindia.com)
- 6 The above standalone unaudited financial results for the Half year ended September 30, 2024 have been prepared by the Company in accordance with Regulation 33 of SEBI (Listing Obligation & Disclosure Requirements) Regulations 2015 (as amended) and were reviewed and recommended by the Audit Committee of the Board and thereafter were approved and taken on record by the Board of Directors in their meeting held on November 14th, 2024, A limited review of the above results has been carried out by the statutory auditors of the company.
- 7 The company has received intimation from suppliers regarding their status under Micro, Small and Medium Enterprises Development Act 2006 and disclosures relating to the amount unpaid as at year end, as required under the said Act, have been provided. But The Company has not provided the interest on outstanding from supplier under Micro, Small and Medium Enterprises as on 30-09-2024.
- 8 The Results for the half-year ended September 30th, 2024 are reviewed by the statutory auditor of the company in compliance with Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- 9 These financial results have been prepared in accordance with the recognition and measurement principles of Accounting Standards ("AS") prescribed section 133 of the Companies Act 2013 (the "Act") read with relevant rules issued thereunder and the other accounting principles generally accepted in India.
- 10 The Earning Per Share (EPS) has been computed in accordance with the Accounting Standard on Earnings Per Share (AS 20). EPS for the half year ended September 30th, 2024, March 2024 and September 2023 are not annualised. The weighted average number of equity shares outstanding during the period has been considered for calculating the basic and diluted earnings per share in accordance with the Accounting Standard 20.

For MEDICAMEN ORGANICS LTD.

  
Director



- 11 The comparative results for the half-year ended September 30, 2024 have been audited or reviewed by the statutory auditors of the Company.
- 12 The figures for the half-year ended March 31<sup>st</sup>, 2024 are balancing figures between audited figures in respect of the full financial year ended March 31<sup>st</sup>, 2024 and the audited half-year ended September 30<sup>th</sup> 2023.
- 13 The company has issued 31,00,000 equity shares of ₹ 10 each at a premium of ₹ 24 each by way of initial public offer ("IPO") and got listed on Emerge Platform of National Stock Exchange of India Limited on June 28<sup>th</sup>, 2024.

14 **Detail of Pending Litigation**

14A	Name of the statute	Nature of the dues	Amount (Rs. in lakhs)		Description	Forum where dispute is pending
	Income Tax Department	Income tax	13.27	2017-18	Assessment year	Commissioner of income tax (Appeal)
	GST	Difference in output tax liability & ITC claimed	5.87	2020-21	Reply is to be filed	Deputy Commissioner (Assessment)-2 Haridwar
	GST	Difference in output tax liability & ITC claimed	89.73	2018-19	Appeal filed	Appeal filed before the Joint Commissioner (Appeals) Dehra Dun
	GST	Difference in output tax liability & ITC claimed	74.51	2019-20	Appeal is to be filed	Appeal to be filed before the Joint Comm. (Appeals) Dehra Dun
	GST	Difference in output tax liability & ITC claimed	17.74	2022-23	Reply is to be filed	Deputy Commissioner (Assessment)-2 Haridwar

14B **Detail of Pending Litigation**

14B	Name of the Party	Nature of the dues	Amount (Rs. in lakhs)	Description	Forum where dispute is pending
	Europa Biocare P Ltd	Civil Case	7.23	The company has filed recovery suit (civil case) against the defaulter party	Rohini (Court)
	M/S Wafture Healthcare P Ltd	Civil Case	5.7	The company has filed recovery suit (civil case) against the defaulter party	Rohini (Court)
	Paseca Health Care	Civil Case	5.53	The company has filed recovery suit (civil case) against the defaulter party	Rohini (Court)
	Ujjwal Overseas	Civil Case	17.17	The company has filed recovery suit (civil case) against the defaulter party	Rohini (Court)

For MEDICAMEN ORGANICS LTD.

*[Signature]*  
Director



- 15 During the period ended September 30 2024, the Company came up with the public issue of 31,00,000 equity shares of Face value of ₹ 10/- each ("equity shares") with the price band of ₹ 32 to 34 through Book Building Method, IPO was open for subscription from Friday, June 21, 2024 to Tuesday, June 25, 2024. The Company has allotted 31,00,000 equity shares of Face value of 10/- each ("equity shares") for cash at a price of ₹ 34/- per equity share (including a share premium of ₹ 24/- per equity share) aggregating to ₹ 1054.00 Lakhs on Wednesday, June 26, 2024. The equity shares of the Company got listed with Emerge platform of National Stock Exchange of India Limited on June 28, 2024. The issue was made in accordance with SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended.

(Rs. In Lakhs)

Object of the Issue as per Prospectus	Utilisation Planned as per prospectus	Total Utilisation up to September 30, 2024	Amount Pending for Utilisation
Funding of expenses proposed to be incurred towards Product registration in the international markets	300.00	4.58	295.42
Plant updation and increase in production capacity	225.00	144.37	80.63
Funding working capital requirements of our Company	400.00	400.00	0.00
General corporate purposes	129.00	129.00	0.00
<b>TOTAL</b>	<b>1054.00</b>	<b>677.96</b>	<b>376.04*</b>

\* The unutilised proceeds are in company's Bank account.

- 16 The company has written off an amount of Rs. 36.24 Lakhs being outstanding balance of supplier due to some material rejections which is subject to confirmation from supplier. further an amount of Rs.16.04 Lakhs from other supplier was written off in the financial year 2023-24 which has been written back in the current period due to disagreement with the party on material rejection.
- 17 Balances of some debtors and creditors are subject to their confirmations.
- 18 As per the assessment of the management, the recoverable amount of assets is higher than it carrying value and hence no impairment of assets needs to be recorded in the financial statements.
- 19 Previous year/period's figures have been regrouped/reclassified wherever necessary to correspond with the current period's classification for comparison.
- 20 As the Company's business activity falls within a single primary business segment i.e. the disclosure requirements as per AS 17 "Segment Reporting" are not applicable.

For &amp; on behalf of Medicamen Organics Limited

For MEDICAMEN ORGANICS LTD.


  
Director

Bal Kishan Gupta  
(Chairman cum Managing Director)

Place: New Delhi  
Date: 14 November

DIN:00032772

2024



# MEDICAMEN ORGANICS LIMITED

Registered Address: 10, Community Centre No 2, Ashok Vihar Phase II New Delhi – 110052, India

CIN: L74899DL1995PLC066416

UNAUDITED CASH FLOW STATEMENT FOR THE HALF YEAR ENDED SEPTEMBER 30<sup>TH</sup>, 2024

(Rs. In Lakhs)

Particulars	Figures as at the end of	
	As At 30.09.2024	As at 30.09.2023
	Unaudited	Audited
<b>Cash flow from operating activities</b>		
Net Profit/(Loss) before tax from continuing operations	218.83	136.25
<b>Non-cash adjustment to reconcile profit before tax to net cash flows</b>		
Provision for Taxation	-	45.65
Depreciation/amortization on continuing operation	36.41	35.85
Interest expense	22.17	28.57
Interest income	-4.29	-0.35
Adjustment for Deffered Tax	0.00	99.51
<b>Operating profit before working capital changes</b>	<b>273.12</b>	<b>345.48</b>
Movements in working capital :		
Increase/(decrease) in trade payables	-124.87	-63.08
Increase / (decrease) in long-term provisions	3.30	2.58
Increase / (decrease) in short-term provisions	-7.57	45.60
Increase/(decrease) in other current liabilities	-16.80	18.49
Decrease/(increase) in trade receivables	-346.51	-297.98
Decrease/(increase) in inventories	-45.55	6.28
Decrease / (increase) in other non-current Assets	-360.71	0.00
Decrease / (increase) in short-term loans and advances	-183.76	42.70
Decrease/(increase) in other current assets	-	-
Direct taxes paid (net of refunds)	-61.43	-45.65
<b>Net cash flow from/ (used in) operating activities (A)</b>	<b>-870.79</b>	<b>54.42</b>
<b>Cash flows from investing activities</b>		
Purchase of fixed assets, including intangible assets and CWIP	-40.85	-112.06
Interest received	4.29	0.35
<b>Net cash flow from/(used in) investing activities (B)</b>	<b>-36.56</b>	<b>-111.71</b>
<b>Cash flows from financing activities</b>		
Proceeds from issuance of share capital	310.00	200.00
Security Premium	744.00	-
Repayment of long-term borrowings	6.68	-5.91
Proceeds from short-term borrowings	15.31	-111.09
Interest paid	-22.17	-28.57
<b>Net cash flow from/(used in) in financing activities (C)</b>	<b>1053.82</b>	<b>54.43</b>
Net increase/(decrease) in cash and cash equivalents (A + B + C)	<b>146.46</b>	<b>-2.86</b>
Cash and cash equivalents at the beginning of the year (D)	55.30	55.91
<b>Cash and cash equivalents at the end of the year ( E)</b>	<b>201.76</b>	<b>53.05</b>
<b>Difference in above D and E</b>	<b>146.46</b>	<b>-2.86</b>

**Notes**

- The above Cash flow statement has been prepared under the indirect method set out in Accounting Standard-3, "Cash Flow Statement" notified under section 133 of the Companies Act 2013, read together with paragraph 7 of the Companies (Accounts) Rules 2014.

For & on behalf of Medicamen Organics Limited

**For MEDICAMEN ORGANICS LTD.**

*Bal Kishan Gupta*

**Director**

Bal Kishan Gupta

(Chairman cum Managing Director)

DIN:00032772

Place: New Delhi

Date: November 14th, 2024





# MEDICAMEN Organics Limited

Regd. & Corporate Office: 10, Community Centre No.2, Ashok Vihar Phase-II, Delhi-110052 (India)

Tel: 011-27430249, 27138171

E-mail: info@mediorganics.in | CIN No: L74899DL1995PLC066416 | GSTIN:07AABCM4302P1ZF

ANNEXURE - B

## Statement of Deviation / Variation in utilisation of funds raised

Name of listed entity	<b>Medicamen Organics Limited</b>					
Mode of Fund Raising	<b>Public Issues</b>					
Date of Raising Funds	26-06-2024 (Allotment Date)					
Amount Raised	Rs.1054.00 Lakhs					
Report filed for Half Year ended	30-09-2024					
Monitoring Agency	Not Applicable					
Monitoring Agency Name, if applicable	Not Applicable					
Is there a Deviation / Variation in use of funds raised	No					
If yes, whether the same is pursuant to change in terms of a contract or objects, which was approved by the shareholders.	Not Applicable					
If Yes, Date of shareholder Approval	No					
Explanation for the Deviation / Variation	Not Applicable					
Comments of the Audit Committee after review	Not Applicable					
Comments of the auditors, if any	Not Applicable					
Objects for which funds have been raised and where there has been a deviation, in the following table						
Original Object	Modified Object, if any	Original Allocation	Modified allocation, if any	Funds Utilised	Amount of Deviation/Variation for the quarter according to applicable object	Remarks if any
Funding of expenses proposed to be incurred towards Product registration in the international markets;	No	3,00,00,000	NA	4,58,355	No	Refer Note
Plant updation and increase in production capacity	No	2,25,00,000	NA	1,44,37,408	No	
Funding working capital requirements of our Company	No	4,00,00,000	NA	4,00,00,000	No	
General corporate purposes	No	1,29,00,000	NA	1,29,00,000	No	

### Notes:

- During the period ended September 30 2024, the Company came up with the public issue of 31,00,000 equity shares of Face value of ₹ 10/- each ("equity shares") with the price band of ₹ 32 to 34 through Book Building Method, IPO was open for subscription from Friday, June 21, 2024 to Tuesday, June 25, 2024. The Company has allotted 31,00,000 equity shares of Face value of 10/- each ("equity shares") for cash at a price of ₹ 34/- per equity share (including a share premium of

### Works:

Unit-1 : Plot No. 60, Sector 6-A, I.I.E. SIDCUL, Haridwar- 249403 (U.K.) | GSTIN: 05AABCM4302P1ZJ

Unit-2 : Plot No. 61, Sector 6-A, I.I.E. SIDCUL, Haridwar- 249403 (U.K.) | GSTIN: 05AABCM4302P3ZH





# MEDICAMEN Organics Limited

Regd. & Corporate Office: 10, Community Centre No.2, Ashok Vihar Phase-II, Delhi-110052 (India)

Tel: 011-27430249, 27138171

E-mail: info@mediorganics.in | CIN No: L74899DL1995PLC066416 | GSTIN:07AABCM4302P1ZF

₹ 24/- per equity share) aggregating to ₹ 1054.00 Lakhs on Wednesday, June 26, 2024. The equity shares of the Company got listed with Emerge platform of National Stock Exchange of India Limited on June 28, 2024. The issue was made in accordance with SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended.

2. Cumulative fund utilized as on September 30, 2024.
3. Part of issue proceeds i.e. Rs.3,76,04,237/- intended to be used for the specified objects, in the terms of Red Herring Prospectus is in the company's bank accounts Rs.3,76,04,237/- as on September 30th, 2024

#### Deviation or variation could mean:

- (a) Deviation in the objects or purposes for which the funds have been raised or
- (b) Deviation in the amount of funds actually utilized as against what was originally disclosed or
- (c) Change in terms of a contract referred to in the fund-raising document i.e. prospectus, letter of offer, etc

For & on behalf of Medicamen Organics Limited

For MEDICAMEN ORGANICS LTD.

Director

Bal Kishan Gupta  
(Chairman cum Managing Director)

Place: New Delhi  
Date: 14 November 2024

#### Works:

Unit-1 : Plot No. 60, Sector 6-A, I.I.E. SIDCUL, Haridwar- 249403 (U.K.) | GSTIN: 05AABCM4302P1ZJ

Unit-2 : Plot No. 61, Sector 6-A, I.I.E. SIDCUL, Haridwar- 249403 (U.K.) | GSTIN: 05AABCM4302P3ZH